金融界消息 截至2025年8月4日收盘，博瑞医药（688166）报收于98.07元，下跌1.19%，换手率3.47%， 成交量14.68万手，成交金额14.49亿元。 资金流向方面，今日主力资金净流入5678.69万元，占比成交额3.92%。其中，超大单净流出2136.60万 元、占成交额1.47%，大单净流入7815.29万元、占成交额5.39%，中单净流出流出1195.96万元、占成交 额0.83%，小单净流出4482.72万元、占成交额3.09%。 天眼查商业履历信息显示，博瑞生物医药(苏州)股份有限公司，成立于2001年，位于苏州市，是一家以 从事医药制造业为主的企业。企业注册资本42246.505万人民币，实缴资本22062.4827万人民币。公司法 定代表人为袁建栋。 通过天眼查大数据分析，博瑞生物医药(苏州)股份有限公司共对外投资了38家企业，参与招投标项目49 次，知识产权方面有商标信息121条，专利信息178条，此外企业还拥有行政许可37个。 来源：金融界 博瑞医药最新一期业绩显示，截至2025一季报，公司营业总收入2.49亿元、同比减少26.81%，归属净利 润1295.98万元，同比减少 ...

Global Core Risks - Geopolitical conflicts, such as the Russia-Ukraine war and tensions in the Middle East, are significant risks affecting global markets, leading to increased oil and gold prices and higher supply chain costs [2][4] - The Federal Reserve's policies and the dollar cycle have profound impacts on global financial markets; prolonged high interest rates could suppress valuations of A-share growth stocks, while fluctuations in the dollar affect foreign capital inflows [2][4] - The strength of China's economic recovery is crucial for the A-share market, with weak real estate and consumption potentially pressuring cyclical stocks, while emerging industries like renewable energy and AI may present structural opportunities [4] Safe Asset Allocation - Gold is highlighted as a key safe-haven asset, with investors encouraged to consider gold ETFs for liquidity and gold stocks for potential upside, particularly during geopolitical crises or currency devaluation [5] - High-dividend assets serve as a defensive tool against market volatility, with banks and utilities providing stable cash flows and low valuations, making them suitable for conservative investors [6] - Government bonds and interest rate bonds are considered low-risk havens, with options for short-term liquidity management through reverse repos and long-term holdings via bond ETFs [7] - Essential consumer goods and pharmaceuticals are identified as defensive sectors with strong demand characteristics, benefiting from brand loyalty and demographic trends [8] A-share Adaptation Strategies - A core-satellite strategy is recommended for portfolio construction, with a core allocation of 60% in high-dividend assets, gold ETFs, and government bonds for stability, while 40% can be flexibly allocated based on market conditions [9] - Investors should focus on policy-driven industry rotations, with potential benefits for sectors like machinery and consumer goods from government incentives, while avoiding high-debt real estate and export-dependent sectors [10] - Dynamic rebalancing of the investment portfolio is advised, adjusting allocations based on market movements, such as increasing high-dividend assets during market downturns [11] Summary and Practical Recommendations - In the context of global risks, geopolitical conflicts and Federal Reserve policies are critical external variables that require ongoing monitoring [12] - A suggested asset allocation includes 20% in gold, 30% in high-dividend assets, and 10% in government bonds to create a safety net against market risks [12] - Conservative investors are encouraged to focus on sectors like electricity, coal, and utilities, while aggressive investors may consider technology and resource sectors during market corrections [12] - Flexibility in response to market changes is essential, with adjustments based on Federal Reserve actions and inflation trends to optimize asset allocation [12][13]

Group 1: Macro Economic Insights - The US non-farm payrolls for July showed a significant drop, with only 73,000 jobs added, far below the expected 110,000, and previous months' data was revised downwards by 258,000 jobs [2][3] - The unemployment rate rose to 4.25%, while hourly wages increased year-on-year to 3.91%, indicating a mixed labor market scenario [2][3] - Market expectations for interest rate cuts have increased, with traders anticipating three cuts totaling 75 basis points by December 2025, reflecting concerns over economic weakness [6][8] Group 2: Chemical Industry Insights - The polyester filament industry is experiencing a concentration of production capacity, with leading companies increasing their market share, resulting in a more orderly supply environment [19][22] - Demand for polyester filament remains stable, with a seasonal uptick expected in the second half of the year as inventory levels are low [20][22] - The cost pressures from raw materials are expected to ease, with oil price fluctuations influencing the cost structure of polyester filament production [21][22] Group 3: Pharmaceutical Industry Insights - The pharmaceutical sector is witnessing a recovery in public fund holdings, with a notable increase in the market value of heavy holdings, indicating a structural rebound [25][28] - Recent policy changes in drug procurement are expected to favor quality over price, potentially stabilizing profit margins for innovative drug and device companies [26][28] - The medical device market is showing signs of recovery, with significant growth in tendering activities, particularly in medical imaging and rehabilitation equipment [27][28] Group 4: North Exchange Market Insights - The North Exchange market has seen a decline in trading activity, with the average daily turnover dropping to approximately 251 billion yuan [31][32] - The overall market valuation remains high, with the North Exchange's price-to-earnings ratio at around 50.9 times, indicating potential for long-term investment value [32][34] - The introduction of new indices and steady progress in IPOs are expected to maintain a high level of market interest and activity [34]

Group 1 - The core viewpoint of the news is that Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. has shown a slight increase in revenue but a decrease in net profit in its latest quarterly report [1] - As of August 1, 2025, the company's stock price closed at 14.31 yuan, down 2.32%, with a trading volume of 239,600 hands and a transaction amount of 353 million yuan [1] - The company's main funds experienced a net outflow of 13.46 million yuan, accounting for 3.82% of the transaction amount, with significant outflows from large orders [1] Group 2 - For the first quarter of 2025, the company reported total operating revenue of 248 million yuan, a year-on-year increase of 4.28%, while the net profit attributable to shareholders decreased by 5.30% to 47.18 million yuan [1] - The company has a current ratio of 4.936, a quick ratio of 4.556, and a debt-to-asset ratio of 35.72% [1] - Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. was established in 2001 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of approximately 2.34 billion yuan [1][2]

Group 1: Investment Rating - The investment rating for MGM China is maintained as "Buy" with a target price raised from HKD 15.5 to HKD 19 [1][6]. Group 2: Core Insights - MGM China reported a net revenue of HKD 8.7 billion for Q2 2025, representing a year-on-year growth of 9% and a quarter-on-quarter growth of 8%, achieving the highest quarterly record in history, with a 72% increase compared to 2019 [1][6]. - The company's adjusted EBITDA reached HKD 2.5 billion, showing a year-on-year increase of 3% and a quarter-on-quarter increase of 6, driven by an unexpected increase in market share, which reached 16.6% in Q2 [1][6]. - The strong performance in gaming revenue is attributed to high-end gaming and concert events, attracting more customers seeking new experiences and quality services [1][6]. - MGM China is focusing on high-end gaming strategies, with a positive outlook for the summer season, and the Alpha Villas in Macau began trial operations in July [1][6]. Group 3: Summary by Sections Section 1: MGM China Q2 2025 Performance - MGM China's Q2 2025 net revenue was HKD 8.7 billion, a 9% increase year-on-year and an 8% increase quarter-on-quarter, with adjusted EBITDA at HKD 2.5 billion, marking a 3% year-on-year increase [1][6]. - The company achieved a market share of 16.6% in Q2, the highest increase among gaming companies, with a strong performance driven by high-end gaming and concert events [1][6]. Section 2: Market Outlook - The outlook for MGM China remains positive, with the summer season expected to maintain strong performance, and new villa suites set to open before the Golden Week in October [1][6]. Section 3: Education Sector Insights - China Oriental Education reported a significant increase in net profit for H1 2025, with a year-on-year growth of 45-50%, corresponding to a profit total of HKD 400-420 million, exceeding expectations [2][9]. - The vocational training sector is expected to see continued growth due to an increase in the number of high school graduates and a rise in the number of students seeking vocational training [2][9]. - The company is focusing on developing new programs tailored to high school graduates, with an expected enrollment increase of approximately 81% in the new 15-month training programs [3][10]. Section 4: Operational Efficiency - The company plans to enhance operational efficiency by optimizing marketing expenditures and improving school capacity utilization, with an expected increase in capacity utilization from 72.7% to 75.3% [4][11]. - The marketing expense ratio is projected to decrease from 23.7% to 22.1%, contributing to an anticipated profit margin expansion of approximately 3.7% to 16.4% in FY 2025 [4][11].

Group 1 - The US job market shows signs of cooling, with July non-farm payrolls increasing by only 74,000, below the expected 104,000, and revisions for May and June totaling a downward adjustment of 258,000 to 19,000 and 14,000 respectively, indicating a significant slowdown since April [1] - The overall US stock market declined, with the S&P 500, Nasdaq, and Dow Jones falling by 1.6%, 2.2%, and 1.2% respectively [1] - The non-farm report reflects a shift in the job market from stability to noticeable cooling, with interest rate cut expectations rising to 60 basis points and a 90% probability of a cut in July [1] Group 2 - Market style rotation is occurring, with funds moving from high valuation sectors to reasonably valued sectors, leading to a gradual rebound in core assets at the bottom [2] - Medical innovation sectors, including CXO (WuXi AppTec/Tigermed), medical devices (Mindray), medical consumption (Aier Eye Hospital/Aimei), and vaccines (Changchun High-tech), are highlighted as core assets that have significantly declined [2] - Many of the top ten component stocks are trading below the historical 20th percentile in terms of valuation, indicating a strong margin of safety [2] - Weak US economic and employment data may accelerate the pace of Federal Reserve interest rate cuts, enhancing global liquidity and benefiting technology stocks [2] - Investors who missed the first half of the medical sector rally can position themselves in the medical innovation ETF (516820) to capitalize on the recovery [2]

机构观点： 凤凰网财经讯 8月4日，三大指数集体低开，沪指低开0.36%，深成指低开0.53%，创业板指低开0.66%， CPO、数字货币等板块指数跌幅居前。 中国银河证券：医药支付端有望边际改善，创新药械有望获益 中国银河证券指出，医药板块估值经历较长时间调整，近期已呈现显著结构性修复趋势，但公募基金重 仓持仓水平仍低于历史均值，2025年在支持引导商保发展的政策背景下，支付端有望边际改善，创新药 械有望获益。1）持续看好医药创新：下半年创新药BD预计仍将持续，国内丙类目录及商保政策有望推 动估值继续提升。2）医药投融资有望复苏：二级市场繁荣有望带来一级市场投融资回升，CXO及上游 景气度向好。3）医疗器械有望触底回升：招投标数据已开始回暖，以旧换新积压需求逐步释放。 华泰证券：国债等利息增值税复征对险资影响有限 华泰证券表示，8月1日，财政部和税务总局发布《关于国债等债券利息收入增值税政策的公告》（《公 告》），自2025年8月8日起，对在该日期之后（含当日）新发行的国债、地方政府债券、金融债券的利 息收入，恢复征收增值税，结束了此前阶段性的政策优惠。险资投资政府债，此前利息收入免征增值税 和所得税，此次 ...

Core Viewpoint - Shanyuan Biological has shown significant financing activity with a net buy of 14.68 million yuan last week, indicating investor interest and potential growth in the biopharmaceutical sector [1] Financing Activity - Shanyuan Biological recorded a total financing buy of 57.79 million yuan and repayment of 43.11 million yuan last week [1] - The company ranked 491st in terms of net financing buy across the market [1] Capital Flow - Over the past 5 days, the main capital inflow into Shanyuan Biological was 71.45 million yuan, with a price increase of 13.32% [1] - In the last 10 days, the capital inflow was 71.48 million yuan, reflecting a price increase of 10.0% [1] Company Profile - Shanyuan Biological Pharmaceutical (Shanghai) Co., Ltd. was established in 2001 and is located in Shanghai, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 410.644 million yuan and a paid-in capital of 316.897548 million yuan [1] - The legal representative of the company is Nie Dongsheng [1] Investment and Intellectual Property - Shanyuan Biological has invested in 7 external companies and participated in 1,602 bidding projects [1] - The company holds 31 trademark registrations and 143 patents, along with 54 administrative licenses [1]

Group 1 - The core viewpoint of the article emphasizes the invalidity of agreements between employers and employees to not pay social insurance fees, reinforcing that such agreements do not hold legal weight and employees can terminate contracts and seek compensation [3][4][6] - The Supreme People's Court's interpretation clarifies that any agreement or promise by an employer or employee to not pay social insurance fees is invalid, and courts will support employees in seeking economic compensation for non-payment [4][6][10] - The article highlights a trend of increasing labor disputes related to welfare benefits, non-compete clauses, and social insurance, indicating a growing need for legal clarity in these areas [1][4] Group 2 - The article discusses a case where an employee, who voluntarily chose not to sign a written labor contract, was denied the right to claim double wages, as the employer was not liable due to the employee's intentional non-compliance [5][6] - It is noted that the interpretation specifies that if an employee intentionally or negligently fails to sign a written labor contract, the employer is not obligated to pay double wages [6][8] - The article also addresses non-compete agreements, stating that such agreements must align with the employee's knowledge of the employer's trade secrets and intellectual property, and any excessive restrictions are deemed invalid [7][8] Group 3 - The article outlines that in cases of subcontracting in the construction industry, the primary contractor remains responsible for paying work-related injury insurance, even if there is no direct labor relationship with the injured worker [9][10] - It emphasizes that the responsibility for labor remuneration and work injury insurance lies with the contractor, regardless of whether the subcontractor has the legal qualifications to operate [10] - The interpretation aims to address common issues in subcontracting practices, ensuring that workers receive timely compensation and protecting their legal rights [10]

8月3日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者参 考。 【品大事】 芯导科技晚发布发行可转换公司债券以及支付现金购买资产并募集配套资金预案，上市公司拟向盛锋、 李晖、黄松、王青松、瞬雷优才发行可转换公司债券以及支付现金形式购买吉瞬科技100%股权、瞬雷 科技17.15%的股权，从而直接及间接持有瞬雷科技100%股权，实现对瞬雷科技的100%控制。本次交易 价格暂定为4.03亿元。瞬雷科技主要从事功率器件的研发、生产和销售；吉瞬科技直接持有瞬雷科技 82.85%的股权，仅为瞬雷科技持股主体。 保利联合晚发布股票交易异常波动公告，股票交易价格连续三个交易日收盘价格跌幅偏离值累计超过 20%，属于股票交易异常波动情况。公司目前经营正常，近期公司经营情况及内外部经营环境未发生重 大变化。 芯导科技：拟购买吉瞬科技100%股权、瞬雷科技17.15%股权，实现对瞬雷科技100%控制 拓山重工：近期经营情况正常，内外部经营环境未发生重大变化 拓山重工晚公告，公司股票连续三个交易日收盘价格跌幅偏离值累计超过20%，属于股票交易异常波动 情况。公司近期经营情况正常，内外部经营环境未发生 ...